Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40986 | 1.00 | TDP1 (0.38) | TDP1TSHRCYP3A4TXNRD1CYP19A1 | |
| Methylamine SCHEMBL6028022 | 0.94 | TSHR (0.38) | TDP1TSHRCYP3A4TXNRD1ALDH1A1 | |
| SCHEMBL31364996 | 0.81 | TDP1 (0.44) | TDP1TSHRCYP3A4TXNRD1CYP19A1 | |
| SCHEMBL29154637 | 0.81 | GPR35 (0.43) | TDP1TSHRCYP3A4ALDH1A1MAPK1 | |
| SCHEMBL28029112 | 0.81 | ALDH1A1 (0.37) | TDP1TSHRCYP3A4TXNRD1CYP19A1 | |
| SCHEMBL14665468 | 0.79 | TDP1 (0.44) | TDP1TSHRCYP3A4TXNRD1ALDH1A1 | |
| SCHEMBL1582439 | 0.79 | TDP1 (0.42) | TDP1TSHRCYP3A4TXNRD1CYP19A1 | |
| SCHEMBL31219064 | 0.79 | TXNRD1 (0.50) | TDP1TSHRCYP3A4TXNRD1ALDH1A1 | |
| SCHEMBL3273393 | 0.79 | TXNRD1 (0.50) | TDP1TSHRCYP3A4TXNRD1ALDH1A1 | |
| SCHEMBL3040192 | 0.79 | CTSB (0.51) | TDP1TSHRCYP3A4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025217330-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-115867556-B | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-119451951-A | Compounds for inhibition of KIF18A | 沃拉斯查疗法公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025034613-A1 | 3H-IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AS NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025008060-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-115867539-A | 2, 3-dihydro-1H-pyrrolo [3,2-b ] pyridine derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115836064-A | Triazine derivative with EGFR (epidermal growth factor receptor) inhibitory activity and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115701429-A | 4- (1H-indole-1-yl) pyrimidine-2-amino derivative and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-02-10 | — | — | CN | disclosed |
| CN-114957242-A | Preparation and application of pyrido-heterocyclic compound as kinase inhibitor | 药雅科技(上海)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-110642838-B | EGFR inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110642836-B | EGFR inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114437065-A | Heterocyclic compounds, their preparation and use | 益方生物科技(上海)股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3972967-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | TDP1 3747/4885TSHR 1324/4885CYP3A4 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.